| Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis F Conforti, L Pala, V Bagnardi, T De Pas, M Martinetti, G Viale, RD Gelber, ... The Lancet Oncology 19 (6), 737-746, 2018 | 778 | 2018 |
| Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients PF Ferrucci, S Gandini, A Battaglia, S Alfieri, AM Di Giacomo, ... British journal of cancer 112 (12), 1904-1910, 2015 | 229 | 2015 |
| Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma PF Ferrucci, L Pala, F Conforti, E Cocorocchio Cancers 13 (6), 1383, 2021 | 186 | 2021 |
| Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis F Conforti, L Pala, V Bagnardi, G Viale, T De Pas, E Pagan, ... JNCI: Journal of the National Cancer Institute 111 (8), 772-781, 2019 | 175 | 2019 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 172 | 2020 |
| The role of systemic therapy in the management of sinonasal cancer: a critical review P Bossi, NF Saba, JB Vermorken, P Strojan, L Pala, R De Bree, ... Cancer treatment reviews 41 (10), 836-843, 2015 | 116 | 2015 |
| Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis F Conforti, L Pala, I Sala, C Oriecuia, T De Pas, C Specchia, R Graffeo, ... Bmj 375, 2021 | 90 | 2021 |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ... Nature 606 (7915), 797-803, 2022 | 69 | 2022 |
| Thymic epithelial tumors: From biology to treatment F Conforti, L Pala, G Giaccone, T De Pas Cancer treatment reviews 86, 102014, 2020 | 64 | 2020 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 61 | 2021 |
| Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion F Conforti, L Pala, E Pagan, V Bagnardi, T De Pas, P Queirolo, ... Clinical Cancer Research 27 (15), 4311-4324, 2021 | 58 | 2021 |
| Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ... European Journal of Cancer 134, 19-28, 2020 | 57 | 2020 |
| Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta … F Conforti, L Pala, E Pagan, C Corti, V Bagnardi, P Queirolo, C Catania, ... ESMO open 6 (5), 100251, 2021 | 50 | 2021 |
| Prognostic significance of hematological profiles in melanoma patients S Gandini, PF Ferrucci, E Botteri, G Tosti, M Barberis, L Pala, A Battaglia, ... International journal of cancer 139 (7), 1618-1625, 2016 | 42 | 2016 |
| Anti-PD1 antibodies in patients aged≥ 75 years with metastatic melanoma: a retrospective multicentre study L Ridolfi, F De Rosa, E Petracci, ET Tanda, E Marra, J Pigozzo, ... Journal of geriatric oncology 11 (3), 515-522, 2020 | 37 | 2020 |
| Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area S Alfieri, NA Iacovelli, S Marceglia, I Lasorsa, C Resteghini, F Taverna, ... Oncotarget 8 (29), 47780, 2017 | 37 | 2017 |
| Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma PF Ferrucci, S Gandini, E Cocorocchio, L Pala, F Baldini, M Mosconi, ... Oncotarget 8 (45), 79809, 2017 | 36 | 2017 |
| Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial F Conforti, PA Zucali, L Pala, C Catania, V Bagnardi, I Sala, P Della Vigna, ... The Lancet Oncology 23 (10), 1287-1296, 2022 | 29 | 2022 |
| Temporal course and predictive factors of analgesic opioid requirement for chemoradiation‐induced oral mucositis in oropharyngeal cancer S Alfieri, CI Ripamonti, S Marceglia, E Orlandi, NA Iacovelli, R Granata, ... Head & Neck 38 (S1), E1521-E1527, 2016 | 29 | 2016 |
| Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations F Conforti, L Pala, V Bagnardi, T De Pas, M Colleoni, M Buyse, ... JAMA oncology 8 (11), 1668-1675, 2022 | 27 | 2022 |
